All‐cause mortality · exacerbations of COPD
Antibiotics showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Treatment failure within 4 weeks ‐ current drugs only ‐ inpatient · exacerbations of COPD
Antibiotics showed no clear difference in treatment failure within 4 weeks ‐ current drugs only ‐ inpatient compared with placebo (moderate certainty).
1 finding from 1 review
Treatment failure within 4 weeks ‐ drugs not currently used ‐ ICU · exacerbations of COPD
Antibiotics probably leads to lower treatment failure within 4 weeks ‐ drugs not currently used ‐ ICU compared with placebo (moderate certainty).
1 finding from 1 review
Length of stay (inpatients only) · exacerbations of COPD
1 finding from 1 review
Duration of hospital stay (days) ‐ ICU patients · exacerbations of COPD
1 finding from 1 review
Inpatient mortality · exacerbations of COPD
Antibiotics showed no clear difference in all‐cause mortality ‐ inpatients compared with placebo (moderate certainty).
1 finding from 1 review
ICU mortality · exacerbations of COPD
Antibiotics probably leads to lower all‐cause mortality ‐ ICU patients compared with placebo (moderate certainty).
1 finding from 1 review
Diarrhoea · exacerbations of COPD
Antibiotics showed no clear difference in adverse events ‐ diarrhoea compared with placebo overall (moderate certainty).
1 finding from 1 review
Number of participants who were not cured at · children < 24 months with ongoing symptoms (cough/wheeze) post‐acute bronchiolitis
Antibiotics showed no clear difference in number of participants who were not cured at compared with placebo or no treatment (low certainty).
1 finding from 1 review
Number of participants rehospitalised for a respiratory illness · children < 24 months with ongoing symptoms (cough/wheeze) post‐acute bronchiolitis
Antibiotics showed no clear difference in number of participants rehospitalised for a respiratory illness compared with placebo or no treatment (low certainty).
1 finding from 1 review
Proportion of participants with recurrent wheeze · children < 24 months with ongoing symptoms (cough/wheeze) post‐acute bronchiolitis
Antibiotics showed no clear difference in proportion of participants with recurrent wheeze compared with placebo or no treatment (low certainty).
1 finding from 1 review
Number of participants requiring antibiotics · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant probably leads to lower number of participants requiring antibiotics compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations requiring antibiotics · management of bronchiectasis
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to lower exacerbations requiring steroids or antibiotics or both: number of… compared with formoterol (high certainty).
1 finding from 1 review
Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes any COPD exacerbation that requires short‐burst oral corticosteroids… compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Exacerbations requiring antibiotics · people with non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Umeclidinium bromide leads to lower number of participants with exacerbations requiring steroids,… compared with placebo (high certainty).
1 finding from 1 review
Number of courses of antibiotics · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review